Cytek Biosciences financials
$5.76+0.35%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $201.5M | $200.5M | $193.0M | $164.0M | $128.0M |
| Gross profit | $104.5M | $111.1M | $109.4M | $101.0M | $79.1M |
| Gross margin | 51.8% | 55.4% | 56.7% | 61.6% | 61.9% |
| Operating income | -$40.4M | -$20.5M | -$27.8M | -$1.8M | $9.2M |
| Net income | -$66.5M | -$6.0M | -$12.1M | $2.6M | $0.00 |
| Net margin | −33.0% | −3.0% | −6.3% | 1.6% | 0.0% |
| Diluted EPS | $-0.52 | $-0.05 | $-0.09 | $0.02 | $0.00 |
| EBITDA | -$32.8M | -$13.3M | -$21.8M | $688.0K | $9.2M |
| Operating cash flow | -$4.7M | $25.4M | $5.3M | -$12.2M | $4.6M |
| Free cash flow | -$8.8M | $21.9M | $633.0K | -$22.0M | $266.0K |
| Diluted shares | 127.7M | 130.6M | 135.3M | 138.6M | 81.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $90.9M | $98.7M | $167.3M | $296.6M | $364.6M |
| Short-term investments | $170.7M | $179.1M | $95.1M | $44.5M | $0.00 |
| Total debt | $525.0K | $1.1M | $1.6M | $2.3M | $0.00 |
| Total assets | $461.5M | $499.5M | $494.5M | $519.5M | $463.3M |
| Total liabilities | $119.8M | $103.8M | $101.4M | $93.9M | $57.9M |
| Shareholders' equity | $341.7M | $395.7M | $393.1M | $425.5M | $405.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology